Drugs / NBI-6024
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00873561 Comparator | Dec 2001 → Apr 2006 | type 1 diabetes mellitus | Neurocrine Biosciences | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2002-01-03 | Neurocrine Biosciences | Neurocrine Biosciences and Taisho Pharmaceutical Initiate A Pivotal Phase IIb Clinical Trial for NBI-6024, A Therapeutic Vaccine for the Treatment of Type I Diabetes gcs-web.com ↗ |
| 2001-02-21 | Neurocrine Biosciences | Neurocrine Biosciences Announces Expansion of NBI-6024 Clinical Program to the United States gcs-web.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NBI-6024 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00873561 ↗ |
| Action | Inhibit | “designed to inhibit autoreactive T-cells” PMID 19690081 ↗ Aug 2009 |
| Modality | Peptide | “an altered peptide ligand, NBI-6024” NCT00873561 ↗ |
| Route | Subcutaneous | “repeated subcutaneous injections of the altered peptide ligand, NBI-6024” PMID 19690081 ↗ Aug 2009 |